Provided by Tiger Trade Technology Pte. Ltd.

Merck

145.60
+3.222.26%
Post-market: 146.310.7130+0.49%19:57 EDT
Volume:9.29M
Turnover:1.35B
Market Cap:359.22B
PE:114.39
High:146.68
Open:141.37
Low:141.36
Close:142.38
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.11
T/O Rate:0.38%
Dividend:3.32
Dividend Rate:2.28%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.57
PE(LYR):20.00

Loading ...

Movement Alert|Merck Rises 3.02% in Regular Trading, EU Injunction Against Keytruda SC Seen Benefiting Halozyme

Market Focus
·
9 hours ago

Sector Update: Healthcare

MT Newswires Live
·
9 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
10 hours ago

Pharma Stocks Jump With Novavax up 12%, Moderna up 6%

Tiger Newspress
·
Yesterday

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Yesterday

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Yesterday

Wells Fargo Adjusts Price Target on Merck & Co to $165 From $170

MT Newswires Live
·
Yesterday

Merck & Company (MRK) Receives a Buy from BMO Capital

TIPRANKS
·
Oct 08

Health Care up on Defensive Bias

Dow Jones
·
Oct 08

US Stocks on the MOVE-Halozyme, Moderna, Merck

Reuters
·
Oct 08

Sector Update: Healthcare

MT Newswires Live
·
Oct 08

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
Oct 08

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
Oct 08

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07